EGFR and neoplasm: One hypothesis arising from this observation is that certain co-occurring alterations present in an EGFR-mutant tumor could modulate sensitivity to EGFR TKI treatment and explain, in part, the variable magnitude and duration of antitumor treatment responses in patients.